Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: KRAS G12D Mutation Clear all
Recruiting Phase 1 Interventional

A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

NCT07456046
View directory record Official record
Conditions
KRAS P.G12D
Interventions
D3S-003
Drug
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
New Haven, Connecticut • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

QTX3034 in Patients With KRAS G12D Mutation

NCT06227377
View directory record Official record
Conditions
Solid Tumors
Interventions
QTX3034, Cetuximab
Drug · Combination Product
Lead sponsor
Quanta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

NCT07020221
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Interventions
VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine, Gemcitabine + Nab-paclitaxel
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

NCT07566052
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Setidegrasib, Docetaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Glendale, California • San Francisco, California • Edison, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559
View directory record Official record
Conditions
Solid Tumor
Interventions
Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
Duarte, California • Santa Monica, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

NCT07777822
View directory record Official record
Conditions
NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung Cancer (NSCLC), Metastatic NSCLC - Non-Small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions
zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

NCT06797336
View directory record Official record
Conditions
Solid Tumor
Interventions
PT0253, Chemotherapy Combination 1, Chemotherapy Combination 2, Chemotherapy Combination 3, Cetuximab
Drug
Lead sponsor
PAQ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03745326
View directory record Official record
Conditions
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

NCT07535112
View directory record Official record
Conditions
Advanced/Metastatic Colorectal Adenocarcinoma
Interventions
BAY 3771249, Cetuximab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Phoenix, Arizona • Duarte, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

NCT06690281
View directory record Official record
Conditions
Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma, Duodenal Cancer, Colorectal Cancer, Small Bowel Cancer, Metastatic Cancers
Interventions
KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

NCT07207707
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
KQB548
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 17, 2026, 5:15 AM EDT